COPD and Asthma Devices Market

COPD and Asthma Devices Market:

The global COPD and asthma devices market size reached USD 45.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 69.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032. The market growth is primarily driven by continual technological advancements in smart inhalers with real-time monitoring capabilities, growing prevalence of respiratory conditions, an enhanced emphasis on personalized treatment options for more accurate drug delivery and increasing demand in emerging markets due to improved healthcare access.

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness. On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs. Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks. These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.

COPD and Asthma Devices Market Trends:

Increased Focus on Personalized Treatment Options

The shift towards personalized medicine is causing a substantial effect on the COPD and asthma devices market share, as manufacturers focus on offering solutions tailored to individual patient requirements. Customizable inhalers and nebulizers are becoming more prominent, designed to enhance patient comfort and treatment precision. Personalized dosing systems ensure accurate medication delivery, minimizing side effects and augmenting overall treatment effectiveness. Additionally, the rise of biologic therapies targeting specific molecular pathways involved in respiratory conditions, is encouraging the use of specialized and advanced delivery devices. This personalized approach allows for more effective management of chronic respiratory diseases. As demand for these customized solutions grows, the market is expected to expand, reflecting a broader trend towards individualized healthcare in respiratory treatment.

Technological Advancements in Inhaler Design

Ongoing innovations in inhaler technology are leading the market according to the latest COPD and asthma devices market trends, transforming the management of these respiratory conditions. Smart inhalers, equipped with sensors and Bluetooth connectivity, enable real-time monitoring of medication usage and adherence. This advancement allows patients and healthcare providers to track inhalation patterns and adjust treatments for improved disease control. The integration of mobile apps further supports this by offering reminders, symptom tracking, and data sharing with clinicians. As digital health solutions gain wider adoption, the demand for smart inhalers is rising, which is contributing to the overall growth of the COPD and asthma devices market.

Rising Demand in Emerging Markets

The COPD and asthma devices market size is witnessing strong growth in demand from emerging economies. Factors such as rapid urbanization, rising air pollution levels, and higher smoking rates are contributing to the prevalence of respiratory conditions in regions such as Asia-Pacific, Latin America, and the Middle East. Around 1.1 billion individuals over the age of 15 and over smoke, with 80% residing in low and middle income countries (LMICs). Rising smoking rates, especially among adolescents, pose growing health and economic burdens without stricter controls. Governments and healthcare systems in these regions are investing in better diagnostic tools and treatment devices to address the growing burden of COPD and asthma. Additionally, improved access to healthcare and the increasing adoption of portable inhalers and nebulizers are augmenting market growth in these regions, making emerging markets key centres for future expansion.

COPD and Asthma Devices Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global COPD and asthma devices market report, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

• Inhalers
  • Drug Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers
• Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers
     

Breakup by Indication:

• Asthma
• COPD
   

Breakup by Distribution Channel:

• Retail Pharmacies
• Hospitals
• Online Pharmacies
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global COPD and asthma devices market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

• Adherium Limited
• Aristopharma Ltd.
• AstraZeneca PLC
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Cohero Health Inc.
• Koninklijke Philips N.V.
• Omron Corporation
• Pari Respiratory Equipment Inc.
• Recipharm AB
• Verona Pharma plc
   

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

COPD and Asthma Devices Market News:

• September 27, 2024: The FDA has approved Dupixent (dupilumab) as the first biologic for treating adults with inadequately controlled COPD and an eosinophilic phenotype in the US. This approval follows similar decisions in the EU and China, based on two pivotal phase 3 studies (BOREAS and NOTUS) showing significant reductions in exacerbations and improved lung function and quality of life compared to placebo. Dupixent is already the leading biologic for various conditions and now provides COPD patients with a new therapeutic option, offering better disease management.
• June 1, 2024: Boehringer Ingelheim launched a new program to limit out-of-pocket costs to $35 per month for eligible patients using their inhalers for COPD and asthma. The initiative aims to render the inhalers more affordable and accessible, particularly for uninsured or underinsured patients. The reduced cost will be automatically applied at participating pharmacies for patients with commercial insurance, and a savings card is available for other eligible patients. The program covers a range of inhalers and is part of Boehringer's broader commitment to supporting patient access to essential medications.

COPD and Asthma Devices market Report Scope: